PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-26.17%
Negative ROE while Healthcare median is 0.95%. Seth Klarman would investigate if capital structure or industry issues are at play.
13636.67%
ROA of 13636.67% while Healthcare median is zero. Peter Lynch would see if minimal profitability can widen over time.
13.77%
ROCE exceeding 1.5x Healthcare median of 0.82%. Joel Greenblatt would look for a high return on incremental capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.